संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

akorn - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 25 mg in 1 ml - levofloxacin oral solution is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin- susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonasaeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumon

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

akorn - alfentanil hydrochloride (unii: 11s92g0tiw) (alfentanil - unii:1n74hm2bs7) - alfentanil 500 ug in 1 ml - alfentanil hcl injection is indicated: see dosage chart for more complete information on the use of alfentanil hcl injection. alfentanil is contraindicated in patients with known hypersensitivity to the drug or known intolerance to other opioid agonists. alfentanil is a schedule ii controlled drug substance that can produce drug dependence of the morphine type and therefore has the potential for being abused. opioid analgesics have been associated with abuse and dependence in health care providers and others with ready access to such drugs. alfentanil should be handled accordingly.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

akorn consumer health - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - capsaicin .25 mg in 1 g - topical analgesic

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

akorn consumer health - red pepper (unii: 6m47g7c4sy) (red pepper - unii:6m47g7c4sy) - red pepper 4 [hp_x] in 20 ml

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

vetone - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i) - this product is indicated for the treatment of superficial bacterial infections of the eyelid and conjunctiva of dogs and cats when due to organisms susceptible to one or more of the antibiotics contained in the ointment. laboratory tests should be conducted including in vitro culturing and susceptibility tests on samples collected prior to treatment.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - melarsomine dihydrochloride (unii: 9cva716q71) (melarsomine - unii:374gj0s41a) - immiticide sterile power is indicated for the treatment of stabilized class 1a , 2b , and 3c heartworm disease caused by immature (4 month-old, stage l5 ) to mature adult infections of dirofilaria immitis in dogs. heartworm disease classification : the following parameters were used to classify the dogs in the clinical field trials for immiticide. other parameters may be considered. as a general rule, conservative treatment should be employed since heartworm disease is serious and potentially fatal. if there is evidence of a high worm burden, patients should be categorized as class 3. a class 1: patients in this category are characterized as having asymptomatic to mild heartworm disease. no radiographic signs or signs of anemia are evident. patients with mild disease may have subjective signs such as a general loss of condition, fatigue on exercise, or occasional cough; however, no objective radiographic or other abnormal laboratory parameters will be present. b class 2: patients in this category are characterized as having moderate heartworm disease. radiographic signs or signs of anemia [packed cell volume (pcv) less than 30% but greater than 20%, or other hematologic parameters below normal] are evident. mild proteinuria (2+) may be present. radiographic signs may include right ventricular enlargement, slight pulmonary artery enlargement, or circumscribed perivascular densities plus mixed alveolar/interstitial lesions. patients may be free of subjective clinical signs or may have a general loss of condition, fatigue on exercise, or occasional cough. if necessary, patients should be stabilized prior to treatment. c class 3: patients in this category are characterized as having severe heartworm disease. these patients have a guarded prognosis. subjective signs of disease may include cardiac cachexia (wasting), constant fatigue, persistent cough, dyspnea, or other signs associated with right heart failure such as ascites and/or jugular pulse. radiographic signs may include right ventricular enlargement or right ventricular plus right atrial enlargement, severe pulmonary artery enlargement, circumscribed to chronic mixed patterns and diffuse patterns of pulmonary densities or radiographic signs of thromboembolism. signs of significant anemia (pcv <20% or other hematologic abnormalities) may be present. proteinuria (>2+) may be present. patients may have only moderate clinical signs and significant laboratory or radiographic alterations or they may have significant clinical signs with only moderate laboratory and radiographic signs and be categorized as class 3. patients in class 3 should be stabilized prior to treatment and then administered the alternate dosing regime (see precautions and dosage and administration ). immiticide is contraindicated in dogs with very severe (class 4) heartworm disease. patients in this category have caval syndrome (d. immitis present in the venae cavae and right atrium).

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

akorn - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine ointment usp, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. it is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of lidocaine ointment usp, 5%.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

akorn - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam 2 mg in 1 ml - lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam is contraindicated in patients with

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

akorn - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - zoledronic acid injection is indicated for treatment of paget's disease of bone in men and women. treatment is indicated in patients with paget's disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see clinical studies (14.5) ]. zoledronic acid injection is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.2) ] - creatinine clearance less than 35 ml/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see warnings and precautions (5.3) ] - known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see adverse reactions (6.2) ]. pregnancy category d [see warnings and precautions (5.6) ].

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

akorn - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 25 mg in 1 ml - levofloxacin injection is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1) ]. levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphyloc